Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

5th Generation cTnT in ED ACSCompleted
NCT03590535N/AUpdated Jul 21, 2022
Sponsor: Columbia University
Acute Coronary Syndrome
United States
AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast CancerTerminated
NCT03147040Phase 2Updated Jul 19, 2022
Sponsor: The Netherlands Cancer Institute
Breast Cancer
Netherlands
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)Completed
NCT02425891Phase 3Updated Jul 19, 2022
Sponsor: Hoffmann-La Roche
Triple Negative Breast Cancer
United States, Argentina, Australia, Austria, Belgium +35 more
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyTerminated
NCT02340221Phase 3Updated Jul 12, 2022
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, Austria, Bosnia and Herzegovina, Bulgaria +23 more
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisCompleted
NCT02115997Phase 4Updated Jul 6, 2022
Sponsor: Hoffmann-La Roche
Wegener's Granulomatosis or Microscopic Polyangiitis
India
A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and ComorbiditiesCompleted
NCT02915224N/AUpdated Jun 28, 2022
Sponsor: Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Greece
A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor TherapyTerminated
NCT03584009Phase 2Updated Jun 28, 2022
Sponsor: Hoffmann-La Roche
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
United States, Australia, Canada, Germany, United Kingdom
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompleted
NCT00976911Phase 3Updated Jun 21, 2022
Sponsor: Hoffmann-La Roche
Ovarian Cancer
Belgium, Bosnia and Herzegovina, Denmark, Finland, France +9 more
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete RemissionTerminated
NCT03850535Phase 1, Phase 2Updated Jun 21, 2022
Sponsor: Hoffmann-La Roche
Acute Myeloid Leukemia
United States, Australia, France, Italy, Spain
A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD)Completed
NCT03611075Phase 1Updated Jun 21, 2022
Sponsor: Hoffmann-La Roche
Autism Spectrum Disorder
United States, Canada, United Kingdom
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompleted
NCT01966471Phase 3Updated Jun 14, 2022
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Australia, Belgium, Bosnia and Herzegovina, Brazil +31 more
Efficacy and Safety of T+A+RAD in HCCUnknown
NCT05396937Phase 2Updated May 31, 2022
Sponsor: Fudan University
Hepatocellular Carcinoma
China
Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.Completed
NCT03163732NAUpdated May 9, 2022
Sponsor: Centre Leon Berard
Advanced Solid Tumor
France
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)Completed
NCT02550873Phase 2Updated May 2, 2022
Sponsor: Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
United States, Czechia, Germany, Italy, Netherlands +2 more
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic MelanomaCompleted
NCT01689519Phase 3Updated May 2, 2022
Sponsor: Hoffmann-La Roche
Malignant Melanoma
United States, Australia, Austria, Belgium, Canada +14 more
PRM-151 in the Prevention of Scarring Following TrabeculectomyCompleted
NCT01064817Phase 2Updated Apr 28, 2022
Sponsor: Hoffmann-La Roche
Glaucoma
Belgium, Czechia, Netherlands, United Kingdom
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Completed
NCT01254409Phase 1Updated Apr 20, 2022
Sponsor: Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
United States, Netherlands
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompleted
NCT02631577Phase 1, Phase 2Updated Apr 13, 2022
Sponsor: Hoffmann-La Roche
Lymphoma, Follicular
United States, France
A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's DiseaseUnknown
NCT05326009N/AUpdated Apr 13, 2022
Sponsor: Xuanwu Hospital, Beijing
Alzheimer Disease
China
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Unknown
NCT03126799Phase 2Updated Apr 6, 2022
Sponsor: National Cancer Center, Korea
EGFR Positive Non-small Cell Lung Cancer
South Korea
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR MutationsUnknown
NCT01470716Phase 2Updated Apr 6, 2022
Sponsor: National Cancer Center, Korea
NSCLC Stage II · NSCLC, Stage IIIA
South Korea
Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLCUnknown
NCT03262454Phase 2Updated Apr 6, 2022
Sponsor: National Cancer Center, Korea
Small Cell Lung Cancer Recurrent
South Korea
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentCompleted
NCT01702571Phase 3Updated Apr 4, 2022
Sponsor: Hoffmann-La Roche
Breast Cancer
Argentina, Australia, Austria, Belgium, Brazil +38 more
An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal PolypsCompleted
NCT03478930Phase 3Updated Apr 4, 2022
Sponsor: Hoffmann-La Roche
Nasal Polyps · Chronic Rhinosinusitis
United States, Belgium, Canada, Czechia, France +9 more
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive LymphomaCompleted
NCT02499003Phase 2Updated Mar 31, 2022
Sponsor: Johannes Gutenberg University Mainz
Lymphoma, Non-Hodgkin
Germany

Previous page Next page